A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Enlicitide, the first oral PCSK9 inhibitor, which achieved ~60% reductions in LDL cholesterol in a large placebo‑controlled trial. The drug also lowered non‑HDL cholesterol, ApoB, and lipoprotein(a), with efficacy comparable to injectable PCSK9 therapies. Safety outcomes were similar to placebo, positioning enlicitide as a potent, convenient oral option for long‑term lipid management.

Source : https://www.nejm.org/doi/10.1056/NEJMoa2511002